Current management of obsessive and phobic states

References

• RachmanSHodgsonRObsessions and CompulsionsHillsdale, NJPrentice-Hall1980
   Google Scholar
• BartzJAHollanderEIs obsessive-compulsive disorder an anxiety disorder?Prog Neuropsychopharmacol Biol Psychiatry20063033835216455175
   PubMed Web of Science ®Google Scholar
• FornaroMGabrielliFAlabanoCObsessive-compulsive disorder and related disorders: A comprehensive surveyAnn Gen Psychiatry200918813
   Google Scholar
• Rodrigues TorresAPereira LimaMCEpidemiology of obsessive-compulsive disorder: A reviewRev Bras Psiquiatr20052723724216224614
   PubMed Web of Science ®Google Scholar
• EisenJLPintoAManceboMCDyckIROrlandoMERasmussenSAA 2-year prospective follow-up study of the course of obsessive-compulsive disorderJ Clin Psychiatry2010711033103920797381
   PubMed Web of Science ®Google Scholar
• Rodrigues TorresAPrinceMJBebbingtonPEObsessive-compulsive disorder: Prevalence, comorbidity, impact, and help-seeking in the British national psychiatric morbidity survey of 2000Am J Psychiatry200516319781985
   Web of Science ®Google Scholar
• DenysDZoharJWestenbergHGMThe role of dopamine in obsessive-compulsive disorder: Preclinical and clinical evidenceJ Clin Psychiatry200414111715554783
   PubMed Web of Science ®Google Scholar
• NicoliniHArnoldPNestadtGLanzagortaNKennedyJLOverview of genetics and obsessive-compulsive disorderPsychiatry Res200817071519819022
   PubMed Web of Science ®Google Scholar
• GoddardAWShekharAWhitemanAFMcDougleCJSerotoninergic mechanisms in the treatment of obsessive-compulsive disorderDrug Discov Today20081332533218405845
   PubMed Web of Science ®Google Scholar
• Clomipramine Collaborative GroupClomipramine in the treatment of patients with obsessive-compulsive disorderArch Gen Psychiatry1991487307381883256
   PubMed Web of Science ®Google Scholar
• MarksIMSternRSMawsonDCobbJMcDonaldRClomipramine and exposure for obsessive-compulsive ritualsBr J Psychiatry19801361256986939
   PubMed Web of Science ®Google Scholar
• FoaEBLiebowitzMRKozakMJRandomized, placebo-controlled trial of exposure and ritual prevention, clomipramine and their combination in the treatment of obsessive-compulsive disorderAm J Psychiatry200516215116115625214
   PubMed Web of Science ®Google Scholar
• KatzRJDeVeaugh-GeissTLandauPClomipramine in obsessive-compulsive disorderBiol Psychiatry1990284014142207219
   PubMed Web of Science ®Google Scholar
• BisserbeJCLaneRMFlamentMFFranco-Belgian OCD Study GroupA double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorderEur Psychiatry199712829319698511
   PubMed Web of Science ®Google Scholar
• FreemanCPTrimbleMRDeakinJFStokesTMAshfordJJFluvoxamine versus clomipramine in the treatment of obsessive-compulsive disorder: A multicentre, randomized, double-blind, parallel group comparisonJ Clin Psychiatry1994553013058071291
   PubMed Web of Science ®Google Scholar
• KoranLMMcElroySLDavidsonJRTRasmussenSAHollanderEJenilaMADouble-blind comparison of fluvoxamine and clomipramine in obsessive-compulsive disorder in the United StatesEur Neuropsychopharmacol19955371
   Google Scholar
• HollanderEAllenASteinerMAcute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetineJ Clin Psychiatry2003641113112114628989
   PubMed Web of Science ®Google Scholar
• SaxenaSBrodyALMaidmentKMBaxterLRJrParoxetine treatment of compulsive hoardingJ Psychiatr Res20074148148716790250
   PubMed Web of Science ®Google Scholar
• SteinMBLiebowitzMRLydiardRBPittsCDBushnellWGergelIParoxetine treatment of generalized social phobia (social anxiety disorder): A randomized controlled trialJAMA19982807087139728642
   PubMed Web of Science ®Google Scholar
• DempseyJPRandallPKThomasSEBookSWCarriganMHTreatment of social anxiety with paroxetine: Mediation of changes in anxiety and depression symptomsCompr Psychiatry20095013514119216890
   PubMed Web of Science ®Google Scholar
• SteinDJVersianiMHairTKumarREfficacy of paroxetine for relapse prevention in social anxiety disorder: A 24-week studyArch Gen Psychiatry2002591111111812470127
   PubMed Web of Science ®Google Scholar
• OrdacgiLMendlowiczMVFontenelleLFManagement of obsessive-compulsive disorder with fluvoxamine extended releaseNeuropsychiatr Dis Treat2009530130819557140
   PubMed Web of Science ®Google Scholar
• KoranLMBrombergDHornfeldtCSShepskiJCWangSHollanderEExtended-release fluvoxamine and improvements in quality of life in patients with obsessive-compulsive disorderCompr Psychiatry20105137337920579510
   PubMed Web of Science ®Google Scholar
• MundoEMainaGUslenghiCMulticenter, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorderInt Clin Psychopharmacol200015697610759337
   PubMed Web of Science ®Google Scholar
• MilanfranchiARavagliSLensiPMarazzitiDCassanoGBA double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorderInt Clin Psychopharmacol1997121311369248868
   PubMed Web of Science ®Google Scholar
• SteinMBAbbyJFyerMDDavidsonJRTPollackMHWiitaBFluvoxamine treatment of social phobia (social anxiety disorder): A double-blind, placebo-controlled studyAm J Psychiatry19995675676010327910
   PubMed Web of Science ®Google Scholar
• RavizzaLBarzegaGBellinoSDrug treatment of obsessive-compulsive disorder (OCD): Long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs)Psychopharmacol Bull1996321671738927668
   PubMed Web of Science ®Google Scholar
• HedgesDWWoonFLMAn emerging role for escitalopram in the treatment of obsessive-compulsive disorderNeuropsychiatr Dis Treat2007345546119300574
   PubMedGoogle Scholar
• ZoharJEscitalopram in the treatment of obsessive-compulsive disorderExper Rev Neurother200818455461
   Google Scholar
• SteinDJAndersenEWTonnoirBFinebergNEscitalopram in obsessive-compulsive disorder: A randomized, placebo-controlled paroxetine-referenced, fixed-dose, 24-week studyCurr Med Res Opin2007237011117407626
   PubMed Web of Science ®Google Scholar
• SteinDJCareyPDLochnerCSeedatSFinebergNAndersenEWEscitalopram in obsessive-compulsive disorder: Response of symptom dimensions to pharmacotherapyCNS Spectrum200813492498
   PubMed Web of Science ®Google Scholar
• LaderMStenderKBürgerVNilREfficacy and tolerability of escitalopram in 12 and 24-week treatment of social anxiety disorder: Randomized, double-blind, placebo-controlled, fixed-dose studyDepress Anxiety20041924124815274173
   PubMed Web of Science ®Google Scholar
• FinebergNATonnoirBLemmingOSteinDJEscitalopram prevents relapse of obsessive-compulsive disorderEur Neuropsychopharmacol20071743043917240120
   PubMed Web of Science ®Google Scholar
• SteinDJAndersenEWLaderMEscitalopram versus paroxetine for social anxiety disorder: An analysis of efficacy for different symptom dimensionEur Neuropsychopharmacol200616333816014329
   PubMed Web of Science ®Google Scholar
• MontgomerySANilRDürr-PalNLoftHBoulengerJPA 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorderJ Clin Psychiatry2005661270127816259540
   PubMed Web of Science ®Google Scholar
• MontgomerySAMcIntyreAOsterheiderMA double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study GroupEur Neuropsychopharmacol199331431528364350
   PubMedGoogle Scholar
• BergeronRRavindranAVChaputYSertraline and fluoxetine treatment of obsessive-compulsive disorder: Results of a double-blind, 6-months treatment studyJ Clin Psychopharmacol20022214815411910259
   PubMed Web of Science ®Google Scholar
• TollefsonGDRampeyAHPotvinJHA multicenter investigation of fixed dose fluoxetine in the treatment of obsessive-compulsive disorderArch Gen Psychiatry1994515595678031229
   PubMed Web of Science ®Google Scholar
• FarnamAGoreishizadehMAFarhangSEffectiveness of fluoxetine on various subtypes of obsessive-compulsive disorderArch Iran Med20081152252518759519
   PubMedGoogle Scholar
• PhillipsKARasmussenSAChange in psychosocial functioning and quality of life of patients with body dysmorphic disorder treated with fluoxetine: Placebo-controlled study200445438444
   Google Scholar
• KobakKAGreistJHJeffersonJWKatzelnickDJFluoxetine in social phobia: A double-blind, placebo-controlled pilot studyJ Clin Psychopharmacol20022225726212006895
   PubMed Web of Science ®Google Scholar
• ClarkDMEhiersAMcManusFCognitive therapy vs fluoxetine in generalized social phobia: A randomized placebo-controlled trialJ Consult Clin Psychol2003711058106714622081
   PubMed Web of Science ®Google Scholar
• DavidsonJRTFoaEBHuppertJDFluoxetine, comprehensive cognitive behavioral therapy and placebo in generalized social phobiaArch Gen Psychiatry2004611005101315466674
   PubMed Web of Science ®Google Scholar
• RomanoSGoodmanWTamuraRGonzalesJLong-term treatment of obsessive-compulsive disorder after an acute response: A comparison of fluoxetine versus placeboJ Clin Psychopharmacol200121465211199947
   PubMed Web of Science ®Google Scholar
• MontgomerySAKasperSSteinDJBang HedegaardKLemmingOMCitalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorderInt Clin Psychopharmacol200116758611236072
   PubMed Web of Science ®Google Scholar
• PhillipsKANajjarFAn open-label study of citalopram in body dysmorphic disorderJ Clin Psychiatry20036471572012823088
   PubMed Web of Science ®Google Scholar
• KoranLMChuongHWBullockKDSmithSCCitalopram for compulsive shopping disorder: An open-label study followed by double-blind discontinuationJ Clin Psychiatry20036479379812934980
   PubMed Web of Science ®Google Scholar
• AtmacaMKulogluMTezcanEUnalAEfficacy of citalopram and moclobemide in patients with social phobia: Some preliminary findingsHum Psychopharmacol20021740140512457375
   PubMed Web of Science ®Google Scholar
• BouwerCSteinDJUse of selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobiaJ Affect Disord19984979829574863
   PubMed Web of Science ®Google Scholar
• MarazzitiDDell’OssoLGemignaniACitalopram in refractory obsessive-compulsive disorder: An open studyInt Clin Psychopharmacol20011621521911459335
   PubMed Web of Science ®Google Scholar
• LeinonenELepolaUKoponenHTurtonenJWadeALehtoHCitalopram controls phobic symptoms in patients with panic disorder: Randomized controlled trialJ Psychiatry Neurosci200025243210721681
   PubMed Web of Science ®Google Scholar
• GreistJChouinardGDuBoffEDouble-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorderArch Gen Psychiatry1995522892957702445
   PubMed Web of Science ®Google Scholar
• BogettoFAlbertUMainaGSertraline treatment of obsessive-compulsive disorder: Efficacy and tolerability of a rapid titration regimenEur Neuropsychopharmacol20021218118612007668
   PubMed Web of Science ®Google Scholar
• SousaMBIsolanLROliveiraRRManfroGGCordioliAVA randomized clinical trial of cognitive-behavioral group therapy and sertraline in the treatment of obsessive-compulsive disorderJ Clin Psychiatry2006671133113916889458
   PubMed Web of Science ®Google Scholar
• LiebowitzMRDeMartinisNAWeihsKEfficacy of sertraline in severe generalized social anxiety disorder: Results of a double-blind, placebo-controlled studyJ Clin Psychiatry20036478579212934979
   PubMed Web of Science ®Google Scholar
• Van AmeringenMALaneRMBowenRCSertraline treatment of generalized social phobia: A 20-week, double-blind, placebo-controlled studyAm J Psychiatry200115827528111156811
   PubMed Web of Science ®Google Scholar
• WalkerJRVan AmeringenMASwinsonRPrevention of relapse in generalized social phobia: Results of a 24-week study in responders to 20 weeks of sertraline treatmentJ Clin Psychiatry200020636644
   Google Scholar
• ChouinardGSertraline in the treatment of obsessive-compulsive disorder: Two double-blind, placebo-controlled studiesInt Clin Psychopharmacol19927Suppl 2S37S41
   Web of Science ®Google Scholar
• KoranLMHackett,ERubinAWolkowRRobinsonDEfficacy of sertraline in the long-term treatment of obsessive-compulsive disorderAm J Psychiatry2002159889511772695
   PubMed Web of Science ®Google Scholar
• NinanPTKoranLMKievAHigh-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: A multicenter double-blind trialJ Clin Psychiatry200667152216426083
   PubMed Web of Science ®Google Scholar
• AlbertUAgugliaEMainaGBogettoFVenlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: A preliminary single-blind, 12 week, controlled studyJ Clin Psychiatry2002631004100912444814
   PubMed Web of Science ®Google Scholar
• DenysDvan der WeeNvan MegenHJWestenbergHGA double-blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorderJ Clin Psychopharmacol20032356857514624187
   PubMed Web of Science ®Google Scholar
• DenysDvan der WeeNvan MegenHWestenbergHGA double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorderJ Clin Psychiatry200465374314744166
   PubMed Web of Science ®Google Scholar
• PhelpsNJCatesMEThe role of venlafaxine in the treatment of obsessive compulsive disorderAnn Pharmacother20053913614015585743
   PubMed Web of Science ®Google Scholar
• RickelsKManganoRKhanAA double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorderJ Clin Psychopharmacol20042448849615349004
   PubMed Web of Science ®Google Scholar
• LiebowitzMRGelenbergAJMunjackDVenlafaxine extended release vs placebo and paroxetine in social anxiety disorderArch Gen Psychiatry20056219019815699296
   PubMed Web of Science ®Google Scholar
• SteinMBPollackMHBystitskyAKelseyJEManganoRMEfficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: A 6-month randomized controlled trialPsychopharmacology200517728028815258718
   PubMed Web of Science ®Google Scholar
• Dell’OssoBMundoEMarazzitiDAltamuraACSwitching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive-disorder: A case seriesJ Psychopharmacol20082221021318208931
   PubMed Web of Science ®Google Scholar
• DenysDPharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorderPsychiatr Clin North Am20062955358416650723
   PubMed Web of Science ®Google Scholar
• SteinDJIpserJCBaldwinDSBandelowBTreatment of obsessive-compulsive disorderCNS Spectrum200712Suppl 3S28S35
   Web of Science ®Google Scholar
• PallantiSQuercioliLTreatment-refractory obsessive-compulsive disorder: Methodological issues, operational definitions and therapeutic linesProg Neuropsychopharmacol Biol Psychiatry20063040040216503369
   PubMed Web of Science ®Google Scholar
• KoranLMAugmentation strategies for treatment resistant obsessive-compulsive disorderClin Neuropsychiatry200416571
   Google Scholar
• SkapinakisPPapatheodorouTMavreasVAntipsychotic augmentation of serotoninergic antidepressants in treatment-resistant obsessive-compulsive disorder: A meta-analysis of the randomized controlled trialsEur Neuropsychopharmacol200717799316904298
   PubMed Web of Science ®Google Scholar
• DenysDFinebergNCareyPDSteinDJQuetiapine addition in obsessive-compulsive disorder: Is treatment outcome affected by type and dose of serotonin reuptake inhibitorsBiol Psychiatry20076141241417241831
   PubMed Web of Science ®Google Scholar
• HollanderEBaldini RossiNSoodEPallantiSRisperidone augmentation in treatment-resistant obsessive-compulsive disorder: A double-blind, placebo-controlled studyInt J Neuropsychopharmacol2003639740114604454
   PubMed Web of Science ®Google Scholar
• McDougleCJEppersonCNPeltonGHWasylinkSPriceLHA double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorderArch Gen Psychiatry20005779480110920469
   PubMed Web of Science ®Google Scholar
• SteinDJBouwerCHawkridgeSEmsleyRARisperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disordersJ Clin Psychiatry1997581191229108814
   PubMed Web of Science ®Google Scholar
• LiXMayRSTolbertLCJacksonWTFlournoyJMBaxterLRRisperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: A crossover studyJ Clin Psychiatry20056673674315960567
   PubMed Web of Science ®Google Scholar
• MainaGPessinaEAlbertUBogettoF8 week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorderEur Neuropsychopharmacol20081836437218280710
   PubMed Web of Science ®Google Scholar
• YangKCSuTPChouYHEffectiveness of aripiprazole in treating obsessive compulsive symptomsProg Neuropsychopharmacol Biol Psychiatry20083258558618037548
   PubMed Web of Science ®Google Scholar
• da RochaFFCorreaHSuccessful augmentation with aripiprazole in clomipramine-refractory obsessive-compulsive disorderProg Neuropsychopharmacol Biol Psychiatry2007311550155117692447
   PubMed Web of Science ®Google Scholar
• WeissELPotenzaMNMcDougleCJEppersonCNOlanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: An open label case seriesJ Clin Psychiatry19996052452710485634
   PubMed Web of Science ®Google Scholar
• KoranLMRingoldALElliottMAOlanzapine augmentation for treatment-resistant compulsive disorderJ Clin Psychiatry20006151451710937610
   PubMed Web of Science ®Google Scholar
• BogettoFBellinoSVaschettoPZieroSOlanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): A 12 week-open trialPsychiatry Res200096919811063782
   PubMed Web of Science ®Google Scholar
• BytriskyAAckermanDLRosenRMAugmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: A placebo-controlled trialJ Clin Psychiatry20046556556815119922
   PubMed Web of Science ®Google Scholar
• CareyPDVythilingumBSeedatSMullerJEvan AmeringenMSteinDJQuetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: A double-blind, randomized, placebo-controlled studyBMC Psychiatry20055515667657
   PubMed Web of Science ®Google Scholar
• FinebergNASivakumaranTRobertsAGaleTAdding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: A randomized controlled treatment studyInt Clin Psychopharmacol20052022322615933483
   PubMed Web of Science ®Google Scholar
• DenysDde GeusFvan MegenHJWestenbergHGA double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitorsJ Clin Psychiatry2004651040104815323587
   PubMed Web of Science ®Google Scholar
• VulinkNCDenysDFluitmanSBMeinardiJCWestenbergHGQuetiapine augments the effect of citalopram in non refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled study of 76 patientsJ Clin Psychiatry2009701001100819497245
   PubMed Web of Science ®Google Scholar
• AbramowitzJSEffectiveness of psychological and pharmacological treatment for obsessive-compulsive disorder: A quantitative reviewJ Consult Clin Psychol19976544529103733
   PubMed Web of Science ®Google Scholar
• van BalkomAJde HaanEvan OppenPSpinhovenPHoogduinKAvan DyckRCognitive and behavioural therapies alone versus in combination with fluvoxamine in the treatment of obsessive compulsive disorderJ Nerv Ment Dis19981864924999717867
   PubMed Web of Science ®Google Scholar
• Marques PrazeresAde SouzaWFFontenelleLFCognitive-behavior therapy for obsessive-compulsive disorder: A systematic review of the last decadeRev Bras Psiquiatr20072926227017713699
   PubMed Web of Science ®Google Scholar
• KobakKAGreitJHJeffersonJWKatzelnickDJHenkHJBehavioral versus pharmacological treatments of obsessive compulsive disorder: A meta-analysisPsychopharmacology19981362052169566805
   PubMed Web of Science ®Google Scholar
• PerseTObsessive-compulsive disorder: A treatment reviewJ Clin Psychiatry19884948552892831
   PubMed Web of Science ®Google Scholar
• BiondiMPicardiAIncreased maintenance of obsessive-compulsive disorder remission after integrated serotoninergic treatment and cognitive psychotherapy compared with medication alonePsychother Psychosom20057412312815741763
   PubMed Web of Science ®Google Scholar
• O’ConnorKPAardemaFRobillardSCognitive behaviour therapy and medication in the treatment of obsessive-compulsive disorderActa Psychiatr Scand200611340841916603032
   PubMed Web of Science ®Google Scholar
• ClarkDMEhlersAHackmannACognitive therapy versus exposure and applied relaxation in social phobia: A randomized controlled trialJ Consult Clin Psychol20067456857816822113
   PubMed Web of Science ®Google Scholar
• BlomhoffSHaugTTHellströmKRandomized controlled general practice trial of sertraline, exposure therapy and combined treatment in generalized social phobiaBr J Psychiatry2001179233011435264
   PubMed Web of Science ®Google Scholar
• LiebowitzMRHeimbergRGSchneierFRCognitive-behavioral group therapy versus phenelzine in social phobia: Long-term outcomeDepress Anxiety199910899810604081
   PubMed Web of Science ®Google Scholar
• BlancoCHeimbergRGSchneierFRA placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorderArch Gen Psychiatry20106728629520194829
   PubMed Web of Science ®Google Scholar
• HollanderEKwonJHSteinDJBroatchJRowlandCTHimeleinCAObsessive- compulsive and spectrum disorders: Overview and quality of life issuesJ Clin Psychiatry199657Suppl 8368698678
   PubMed Web of Science ®Google Scholar
• FoaEBGraysonJBSteketeeGSDoppeltHGTurnerRMLatimerPRSuccess and failure in the behavioural treatment of obsessive-compulsivesJ Consult Clin Psychol1983512872976841773
   PubMed Web of Science ®Google Scholar
• GreistJHBehavior therapy for obsessive-compulsive disorderJ Clin Psychiatry199455Suppl60687961534
   PubMed Web of Science ®Google Scholar
• ThorenPAsbergMCronholmBJornestedtLTraskmanLClomipramine treatment of obsessive-compulsive disorder. A controlled clinical trialArch Gen Psychiatry198037128112857436690
   PubMed Web of Science ®Google Scholar
• MainaGAlbertUBogettoFRelapses after discontinuation of drug associated with increased resistance to treatment in obsessive-compulsive disorderInt Clin Psychopharmacol200116333811195258
   PubMed Web of Science ®Google Scholar
• DinizJBMalavazziDMFossaluzaVRisk factors for early treatment discontinuation in patients with obsessive-compulsive disorderClinics (Sao Paolo)201166387393
   PubMed Web of Science ®Google Scholar
• CottrauxJMollardEBouvardMMarksIExposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: One year follow-upPsychiatry Res19934963758140182
   PubMed Web of Science ®Google Scholar
• SapanaRPatelSRSimpsonHBPatient preferences for obsessive-compulsive disorder treatmentJ Clin Psychiatry2010711434143921114948
   PubMed Web of Science ®Google Scholar
• GoodmanWKPriceLHRasmussenSAThe Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliabilityArch Gen Psychiatry198946100610112684084
   PubMed Web of Science ®Google Scholar
• EisenJLPhillipsKABaerLBeerDAAtalaKDRasmussenSAThe Brown Assessment of Beliefs Scale: Reliability and validityAm J Psychiatry19981551021089433346
   PubMed Web of Science ®Google Scholar
• AlonsoPMenchonJMPifarreJLong-term follow up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioural therapyJ Clin Psychopharmacol200162535540
   Google Scholar
• BlackDWMonahanPGableJHoarding and treatment response in 38 nondepressed subjects with obsessive-compulsive disorderJ Clin Psychopharmacol199859420425
   Google Scholar
• ErzegovesiSCavalliniMCCavediniPClinical predictors of drug response in obsessive-compulsive disorderJ Clin Psychopharmacol20012148849111593074
   PubMed Web of Science ®Google Scholar
• MundoEErzegovesiSBellosiLFollow up of obsessive-compulsive patients treated with proserotoninergic agentsJ Clin Psychopharmacol1995152882897593716
   PubMed Web of Science ®Google Scholar
• FontenelleLFMendlowicMVMarquesCVersianiMEarly- and late-onset obsessive-compulsive disorder in adult patients: Exploratory clinical and therapeutic studyJ Psychol Res200337127133
   Web of Science ®Google Scholar
• Mataix-ColsDMarksIMGreistJHKobakKABaerLObsessive-compulsive symptom dimensions as predictors of compliance with and response to behaviour therapy: Results from a controlled trialPsychother Psychosom20027125526212207105
   PubMed Web of Science ®Google Scholar
• ChristensenDDGreistJHThe challenge of obsessive-compulsive disorder hoardingPrim Psychiatry200187986
   Google Scholar
• Mataix-ColsDRauchSLManzoPAJenikeMABaerLUse of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorderAm J Psychiatry19991591409141610484953
   PubMed Web of Science ®Google Scholar
• SteketeeGFrostROWinczeJGreeneKAIDouglassHGroup and individual treatment of compulsive hoarding: A pilot studyBehav Cognit Psychother200028259268
   Google Scholar
• FerrãoYAShavittRGBedinNRClinical feature associated to refractory obsessive compulsive disorderJ Affect Disord20069419920916764938
   PubMed Web of Science ®Google Scholar
• HollanderEBienstockCAKoranLMRefractory obsessive-compulsive disorder: State-of-the-art treatmentJ Clin Psychopharmacol200263Suppl 62029
   Google Scholar
• CatapanoFSperandeoRPerrrisLLanzaroMMajMInsight and resistance in patients with obsessive-compulsive disorderPsychopathology200134626811244376
   PubMed Web of Science ®Google Scholar
• MatzunagaHKiriikeNMatsuiTObsessive-compulsive disorder with poor insightCompr Psychiatry20024315015711893994
   PubMed Web of Science ®Google Scholar
• AlonsoPMenchonJMSegalasCClinical implications of insight assessment in obsessive-compulsive disorderCompr Psychiatry20084930531218396191
   PubMed Web of Science ®Google Scholar
• FoaEBAbramowitzJSFranklinMEKozakMJFeared consequences, fixity of belief, and treatment outcome in patients with obsessive-compulsive disorderBehav Ther199930717724
   Web of Science ®Google Scholar
• HimleJAVan EttenMLJaneckASFischerDJInsight as a predictor of treatment outcome in behavioural group treatment for obsessive-compulsive disorderCogn Ther Res200630661666
   Web of Science ®Google Scholar
• CatapanoFPerrisFFabrazzoMObsessive-compulsive disorder with poor insight: A three year prospective studyProg Neuropsychopharmacol Biol Psychiatry20103432333020015461
   PubMed Web of Science ®Google Scholar
• PoyurovskyMFaragianSPashinianAClinical characteristics of schizotypal-related obsessive-compulsive disorderPsychiatry Res200815925425818378321
   PubMed Web of Science ®Google Scholar
• Ravi KishoreVSamarRJanardhan ReddyYCChandrasekharCRThennarasuKClinical characteristics and treatment response in poor and good insight obsessive-compulsive disorderEur Psychiatry20041920220815196601
   PubMed Web of Science ®Google Scholar
• TurksoyNTukelROzdemirOKaraliAComparison of clinical characteristics in good and poor insight obsessive-compulsive disorderJ Anxiety Disord20021641342312213036
   PubMed Web of Science ®Google Scholar
• LelliotPTNoshirvaniHFBasogluMMarksIMMonteiroWDLObsessive-compulsive beliefs and treatment outcomePsychol Med1988186977022903513
   PubMed Web of Science ®Google Scholar
• SobinCBlundellMLWeillerFGaviganCHaimanCKarayiorgouMEvidence of a schizotypy subtype in OCDJ Psychiatry Res2000341524
   PubMed Web of Science ®Google Scholar